Showing results (91-100 of 647) with videos related to

Sort By:
Pageof 65
Endocrine Reviews|February 25, 2025
Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic RelevanceMaria Apostolopoulou, Vaia Lambadiari, Michael Roden, et al.
BMJ Open|June 26, 2015
Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetesDan Ziegler, Margarete Behler, Maria Schroers-Teuber, et al.
Oncotarget|February 14, 2018
Overexpression of Na+/Mg2+ exchanger SLC41A1 attenuates pro-survival signalingGerhard Sponder, Nasrin Abdulhanan, Nadine Fröhlich, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|May 23, 2014
Modeling glucose and free fatty acid kinetics during insulin-modified intravenous glucose tolerance test in healthy humans: role of counterregulatory responseKarl Thomaseth, Attila Brehm, Alessandra Pavan, et al.
British Journal of Pharmacology|April 10, 2003
Differences in troglitazone action on glucose metabolism in freshly isolated vs long-term incubated rat skeletal muscleFlorian Gras, Barbara Brunmair, Michael Roden, et al.
Clinical Liver Disease|February 8, 2021
Nonalcoholic Fatty Liver Disease and Cardiovascular DiseaseEric M Przybyszewski, Giovanni Targher, Michael Roden, et al.
Diabetes Care|August 28, 2025
Plant-Based Dietary Patterns Associated With Reduced Risk of All-Cause Mortality in Diabetes Subgroups: A Prospective Cohort Study From the UK BiobankEdyta Schaefer, Janett Barbaresko, Michael Roden, et al.
Clinical Chemistry|October 2, 2004
Relationship between serum lipoprotein ratios and insulin resistance in obesityAttila Brehm, Georg Pfeiler, Giovanni Pacini, et al.
Diabetologia|December 7, 2013
Reduction of non-esterified fatty acids improves insulin sensitivity and lowers oxidative stress, but fails to restore oxidative capacity in type 2 diabetes: a randomised clinical trialEsther Phielix, Tomas Jelenik, Peter Nowotny, et al.
Clinics in Liver Disease|May 16, 2026
Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease: Drugs Targeting Obesity and Type 2 DiabetesSonal Kumar, Maria Paula Macedo, Michael Roden, et al.
Pageof 65